1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Samsung Seeks To Scrub US Soliris Patents With A Pair Of USPTO Challenges

Small Pool Of Eculizumab Biosimilar Developers Includes Settler Amgen

 
• By Dean Rudge

Samsung Bioepis has taken to five its number of IPR challenges to Alexion’s US Soliris intellectual property portfolio, filing two simultaneously.

Macro photo of tooth wheel mechanism with PATENTS concept letters
• Source: Shutterstock

With designs on securing US Food and Drug Administration approval for its proposed SB12 biosimilar Soliris (eculizumab) candidate, Samsung Bioepis has filed a pair of petitions with the US Patent and Trademark Office requesting an inter partes review of two US patents shielding Alexion’s rare blood disease monoclonal antibody.

According to Samsung Bioepis, the two US patents, 10,590,189 and 10,703,809, both covering a method of treating paroxysmal nocturnal hemoglobinuria...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 
• By Urtė Fultinavičiūtė

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

Arizonans To Be Offered Up To 80% Discount On Generic Drugs

 
• By Urtė Fultinavičiūtė

Arizona’s governor Katie Hobbs pointed to Trump’s One Big Beautiful Bill and other federal failures as she signed an executive order to increase access to medications in her state.